Indoleamine 2,3-dioxygenase-1 is protective in atherosclerosis and its metabolites provide new opportunities for drug development

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 42, 2015, Pages 13033-13038

  Cole, Jennifer E ^a   Astola, Nagore ^a   Cribbs, Adam P ^a   Goddard, Michael E ^a   Park, Inhye ^a   Green, Patricia ^a   Davies, Alun H ^b   Williams, Richard O ^a   Feldmann, Marc ^a   Monaco, Claudia ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Atherosclerosis; B cell; Cardiovascular disease; Indoleamine 2,3 dioxygenase; Inflammation

Indexed keywords

3,4 DIMETHOXYCINNAMIC ACID; CHEMOKINE; CHOLESTEROL; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; 3-(3,4-DIMETHOXYPHENYL)PROPENOIC ACID; ANTHRANILIC ACID; ANTHRANILIC ACID DERIVATIVE; APOLIPOPROTEIN E; CINNAMIC ACID DERIVATIVE; IDO1 PROTEIN, MOUSE; KYNURENINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROMA; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; B LYMPHOCYTE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME DEFICIENCY; HUMAN; HUMAN CELL; INFLAMMATION; LYMPH NODE CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; ANIMAL; BLOOD; CHEMISTRY; DRUG DESIGN; GENETICS; KNOCKOUT MOUSE; METABOLISM; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CINNAMATES; DRUG DESIGN; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KYNURENINE; MICE; MICE, KNOCKOUT; ORTHO-AMINOBENZOATES; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84947460330     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1517820112     Document Type: Article

References (38)

1. Lozano R, et al. (2012) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380(9859):2095-2128.
2. Smith SC, Jr (2007) Multiple risk factors for cardiovascular disease and diabetes mellitus. Am J Med 120(3, Suppl 1):S3-S11.
3. Bianchi M, Bertini R, Ghezzi P (1988) Induction of indoleamine dioxygenase by interferon in mice: A study with different recombinant interferons and various cytokines. Biochem Biophys Res Commun 152(1):237-242.
4. Fujigaki S, et al. (2001) Lipopolysaccharide induction of indoleamine 2, 3-dioxygenase is mediated dominantly by an IFN-gamma-independent mechanism. Eur J Immunol 31(8):2313-2318.
5. Mellor AL, Munn DH (2004) IDO expression by dendritic cells: Tolerance and tryptophan catabolism. Nat Rev Immunol 4(10):762-774.
6. Wang Y, et al. (2010) Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nat Med 16(3):279-285.
7. Wirleitner B, et al. (2003) Immune activation and degradation of tryptophan in coronary heart disease. Eur J Clin Invest 33(7):550-554.
8. Niinisalo P, et al. (2008) Indoleamine 2, 3-dioxygenase activity associates with cardiovascular risk factors: The Health 2000 study. Scand J Clin Lab Invest 68(8):767-770.
9. Pertovaara M, et al. (2007) Indoleamine 2, 3-dioxygenase enzyme activity correlates with risk factors for atherosclerosis: The Cardiovascular Risk in Young Finns Study. Clin Exp Immunol 148(1):106-111.
10. Pedersen ER, et al. (2015) Associations of plasma kynurenines with risk of acute myocardial infarction in patients with stable angina pectoris. Arterioscler Thromb Vasc Biol 35(2):455-462.
11. Niinisalo P, et al. (2010) Activation of indoleamine 2, 3-dioxygenase-induced tryptophan degradation in advanced atherosclerotic plaques: Tampere Vascular Study. Ann Med 42(1):55-63.
12. Holmes DR, Jr, et al. (2002) Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation 106(10):1243-1250.
13. Inglis JJ, et al. (2007) The anti-allergic drug, N-(3', 4'-dimethoxycinnamonyl) anthranilic acid, exhibits potent anti-inflammatory and analgesic properties in arthritis. Rheumatology (Oxford) 46(9):1428-1432.
14. Platten M, et al. (2005) Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science 310(5749):850-855.
15. Azuma H, Banno K, Yoshimura T (1976) Pharmacological properties of N-(3', 4'- dimethoxycinnamoyl) anthranilic acid (N-5'), a new anti-atopic agent. Br J Pharmacol 58(4):483-488.
16. Narula J, Strauss HW (2007) The popcorn plaques. Nat Med 13(5):532-534.
17. Fallarino F, et al. (2006) The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol 176(11):6752-6761.
18. Stone TW, Darlington LG (2002) Endogenous kynurenines as targets for drug discovery and development. Nat Rev Drug Discov 1(8):609-620.
19. Monaco C, et al. (2004) Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis. Proc Natl Acad Sci USA 101(15):5634-5639.
20. Cole JE, et al. (2011) Unexpected protective role for Toll-like receptor 3 in the arterial wall. Proc Natl Acad Sci USA 108(6):2372-2377.
21. Leung BP, et al. (2003) A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 170(3):1524-1530.
22. Sasaki M, et al. (2003) The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor pravastatin reduces disease activity and inflammation in dextran-sulfate induced colitis. J Pharmacol Exp Ther 305(1):78-85.
23. Youssef S, et al. (2002) The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420(6911):78-84.
24. McCarey DW, et al. (2004) Trial of Atorvastatin in Rheumatoid Arthritis (TARA): Double-blind, randomised placebo-controlled trial. Lancet 363(9426):2015-2021.
25. Zhang L, et al. (2012) The tryptophan metabolite 3-hydroxyanthranilic acid lowers plasma lipids and decreases atherosclerosis in hypercholesterolaemic mice. Eur Heart J 33(16):2025-2034.
26. Polyzos KA, et al. (2015) Inhibition of indoleamine 2, 3-dioxygenase promotes vascular inflammation and increases atherosclerosis in Apoe-/- mice. Cardiovasc Res 106(2): 295-302.
27. Yin W, et al. (2012) Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res 53(1):51-65.
28. Jackson CL, Bennett MR, Biessen EA, Johnson JL, Krams R (2007) Assessment of unstable atherosclerosis in mice. Arterioscler Thromb Vasc Biol 27(4):714-720.
29. van der Wal AC, Becker AE (1999) Atherosclerotic plaque rupture-Pathologic basis of plaque stability and instability. Cardiovasc Res 41(2):334-344.
30. Mestas J, Hughes CC (2004) Of mice and not men: Differences between mouse and human immunology. J Immunol 172(5):2731-2738.
31. Frumento G, et al. (2002) Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2, 3-dioxygenase. J Exp Med 196(4):459-468.
32. Terness P, et al. (2002) Inhibition of allogeneic T cell proliferation by indoleamine 2, 3- dioxygenase-expressing dendritic cells: Mediation of suppression by tryptophan metabolites. J Exp Med 196(4):447-457.
33. Strom AC, et al. (2015) B regulatory cells are increased in hypercholesterolemic mice and protect from lesion development via IL-10. Thromb Haemost, 10.1160/TH14-12-1084.
34. Favre D, et al. (2010) Tryptophan catabolism by indoleamine 2, 3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci Transl Med 2(32):32ra36.
35. Mezrich JD, et al. (2010) An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol 185(6):3190-3198.
36. Weber WP, et al. (2006) Differential effects of the tryptophan metabolite 3-hydroxyanthranilic acid on the proliferation of human CD8+ T cells induced by TCR triggering or homeostatic cytokines. Eur J Immunol 36(2):296-304.
37. Del Prete G, et al. (1993) Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol 150(2):353-360.
38. Metghalchi S, et al. (2015) Indoleamine 2, 3-dioxygenase fine-tunes immune homeostasis in atherosclerosis and colitis through repression of interleukin-10 production. Cell Metab 22(3):460-471.